Consensus Jade Biosciences, Inc.

Stocks

JBIO

US0080642061

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 29/10/2026 HKT			5-day change	1st Jan Change
14.59 ^USD	-1.02%		-1.82%	-5.44%

09-30	Jade Biosciences, Inc. - Special Call
09-30	Jade Biosciences, Inc. Announces Preclinical Data Characterizing Jade301	CI

Evolution of the Average Target: Jade Biosciences, Inc.

Evolution of the Target Price: Jade Biosciences, Inc.

Changes in Analyst Recommendations: Jade Biosciences, Inc.

ce6f511b18dc06ad47b7.8wVZkYnX31Lo4IxacDnO-eYSETs55FKlrMdNaoZ9pCA.ikhvp-iIr2uEsdMvAwiPvbF9RVxepReIm64ZPOUT9U2LRwv12bm6CqmF_w~9a13714caced3035fe28d770fef813fe

Analysts' recommendations: Jade Biosciences, Inc.

09-04	Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says	MT
08-10	Wedbush Adjusts Price Target on Jade Biosciences to $47 From $45, Keeps Outperform Rating	MT
06-15	UBS Initiates Jade Biosciences at Buy With $45 Price Target	MT
06-01	Wedbush Raises Price Target on Jade Biosciences to $45 From $34, Maintains Outperform Rating	MT
05-08	Wedbush Raises Price Target on Jade Biosciences to $34 From $24, Keeps Outperform Rating	MT
05-08	Wedbush Raises Price Target on Jade Biosciences to $34 From $24, Maintains Outperform Rating	MT
03-09	William Blair Initiates Coverage on Jade Biosciences With Outperform Rating	MT
01-07	HC Wainwright Initiates Jade Biosciences at Buy With $25 Price Target	MT
12-24	Wedbush Adjusts Price Target on Jade Biosciences to $24 From $19, Maintains Outperform Rating	MT
11-14	Wedbush Adjusts Price Target on Jade Biosciences to $19 From $18, Maintains Outperform Rating	MT
09/10/25	BTIG Initiates Jade Biosciences at Buy With $28 Price Target	MT
14/08/25	Wedbush Adjusts Price Target on Jade Biosciences to $18 From $17, Maintains Outperform Rating	MT
16/06/25	Guggenheim Upgrades Jade Biosciences to Buy From Neutral, Price Target is $14	MT
05/05/25	Stifel Nicolaus Initiates Coverage on Jade Biosciences With Buy Rating, $19 Price Target	MT
02/05/25	TD Cowen Initiates Coverage on Jade Biosciences With Buy Rating	MT
18/06/24	Guggenheim Downgrades Aerovate Therapeutics to Neutral From Buy	MT
18/06/24	TD Cowen Downgrades Aerovate Therapeutics to Hold From Buy	MT
18/06/24	Evercore ISI Downgrades Aerovate Therapeutics to In Line From Outperform, Adjusts Price Target to $2 From $27	MT
18/06/24	Top Midday Decliners	MT
18/06/24	Jefferies Downgrades Aerovate Therapeutics to Hold From Buy, Cuts Price Target to $2 From $65; Shares Plummet	MT
17/06/24	Wells Fargo Downgrades Aerovate Therapeutics to Equalweight From Overweight, Cuts Price Target to $2 From $35; Shares Plummet	MT
17/06/24	BTIG Downgrades Aerovate Therapeutics to Neutral From Buy	MT
17/06/24	Wedbush Downgrades Aerovate Therapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $41	MT
15/08/23	Wedbush Adjusts Aerovate Therapeutics Price Target to $48 From $50, Maintains Outperform Rating	MT
17/05/23	Wedbush Lowers Aerovate Therapeutics' Price Target to $50 From $54, Keeps Outperform Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	JADE BIOSCIENCES, INC.					+240.06%
	WUXI APPTEC CO., LTD.					+41.32%
	ARGENX SE					+28.63%
	LONZA GROUP AG					+9.56%
	IQVIA HOLDINGS INC.					+12.15%
	BEONE MEDICINES AG					+19.23%
	REVOLUTION MEDICINES, INC.					+39%
	CELLTRION, INC.					+42.31%
	GENMAB A/S					+6.5%
	WUXI BIOLOGICS (CAYMAN) INC.					+35.02%
	Average					+47.38%
	Weighted average by Cap.					+26.72%